El interés en corto de Otis Worldwide da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Otis Worldwide. Los datos de interés en corto se actualizan cada dos semanas.

Otis Worldwide (NYSE:OTIS) Bolsa, Informe de interés en corto

Otis Worldwide

Otis is the largest global elevator and escalator supplier by revenue with around 18% global market share. In 1854 Otis' founder and namesake Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed. The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15- to 20-year useful life of an elevator. As the largest global OEM, Otis has amassed an installed base under service that exceeds 2 million elevators. Its business model is similar to that of its closest competitors Kone, Schindler, and TK Elevator.

Otis Worldwide Corp

UBS analyst Lloyd Walmsley maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $736 to $786.

News

Price Target

Analyst Ratings

UBS Maintains Buy on Meta Platforms, Raises Price Target to $786

UBS analyst Joseph Spak maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Sell and raises the price target from $226 to $259.

TSLA

UBS Maintains Sell on Tesla, Raises Price Target to $259

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and raises the price target from $162 to $176.

NBIX

UBS Maintains Buy on Neurocrine Biosciences, Raises Price Target to $176

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 5 years by 2.84% on an annualized basis producing an average annual return of 15.8%. Currently, AbbVie has a market capitalization of $310.89 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 5 years ago, it would be worth $213.43 today based on a price of $175.93 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738278910_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ABBV

$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today

TD Securities analyst Craig Hutchison maintains MAG Silver (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MAG#TSX">MAG</a>) with a Buy and raises the price target from C$26 to C$27.

TSX:MAG

TD Securities Maintains Buy on MAG Silver, Raises Price Target to C$27

TD Securities analyst Daniel Chan maintains CGI (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GIB#TSX">GIB</a>) with a Buy and raises the price target from C$180 to C$190.

TSX:GIB

TSX:GIB/A

TD Securities Maintains Buy on CGI, Raises Price Target to C$190

Citigroup analyst Ronald Josey maintains Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) with a Buy and raises the price target from $753 to $780.

Citigroup Maintains Buy on Meta Platforms, Raises Price Target to $780

Citigroup analyst Jon Tower maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Neutral and raises the price target from $166 to $185.

Citigroup Maintains Neutral on Brinker International, Raises Price Target to $185

Citigroup analyst Scott Gruber maintains Seadrill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDRL#NYSE">SDRL</a>) with a Buy and lowers the price target from $50 to $46.

SDRL

Citigroup Maintains Buy on Seadrill, Lowers Price Target to $46

American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) has outperformed the market over the past 5 years by 6.37% on an annualized basis producing an average annual return of 19.32%. Currently, American Express has a market capitalization of $223.90 billion. 
Buying $100 In AXP: If an investor had bought $100 of AXP stock 5 years ago, it would be worth $243.47 today based on a price of $318.95 for AXP at the time of writing.
<h3>American Express's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738278015_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning American Express Stock In The Last 5 Years

Citigroup analyst Scott Gruber maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Neutral and raises the price target from $47 to $48.

Citigroup Maintains Neutral on Valaris, Raises Price Target to $48

Citigroup analyst Asiya Merchant maintains Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) with a Buy and lowers the price target from $82 to $80.

Citigroup Maintains Buy on Western Digital, Lowers Price Target to $80

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $285 to $265.

Citigroup Maintains Buy on Danaher, Lowers Price Target to $265

Citigroup analyst George Choi maintains Las Vegas Sands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>) with a Buy and raises the price target from $64.5 to $67.

Citigroup Maintains Buy on Las Vegas Sands, Raises Price Target to $67

Maxim Group analyst Jason McCarthy maintains Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) with a Buy and raises the price target from $8 to $12.

Alterity Therapeutics Limited - American Depositary Shares

ATHE

Maxim Group Maintains Buy on Alterity Therapeutics, Raises Price Target to $12

Earnings

HFBL

CORRECTION: Home Federal Bancorp Q2 EPS $0.33, Flat YoY

Cheniere Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) has outperformed the market over the past 5 years by 18.24% on an annualized basis producing an average annual return of 31.2%. Currently, Cheniere Energy has a market capitalization of $51.65 billion. 
Buying $1000 In LNG: If an investor had bought $1000 of LNG stock 5 years ago, it would be worth $3,918.96 today based on a price of $230.20 for LNG at the time of writing.
<h3>Cheniere Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738277138_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Cheniere Energy 5 Years Ago Would Be Worth This Much Today

Shares of Common Stock are expected to begin trading on the New York Stock Exchange under the ticker symbol "INR." The offering is expected to close on February 3, 2025, subject to customary closing conditions.

IPOs

Infinity Natural Resources Prices Public Offering Of 13.25M Shares Of Class A Common Stock At $20.00 Per Share

Maxim Group analyst Allen Klee initiates coverage on Orangekloud Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORKT#NASDAQ">ORKT</a>) with a Buy rating and announces Price Target of $5.

Initiation

ORKT

Maxim Group Initiates Coverage On Orangekloud Technology with Buy Rating, Announces Price Target of $5

Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) shares are falling in extended trading Thursday after the company <a href="https://www.benzinga.com/pressreleases/25/01/b43355741/walgreens-boots-alliance-suspends-quarterly-dividend-as-company-continues-disciplined-execution-ag">suspended its quarterly dividend</a>.
What Happened: After the market close on Thursday, Walgreens announced its board is suspending its cash dividend as management continues to evaluate its capital allocation policy as part of a longer-term turnaround strategy.
The suspended dividend is expected to help strengthen the company&#8217;s balance sheet by reducing debt over time and improving free cash flow.
&#8220;The company&#8217;s cash needs over the next several years, including with respect to litigation and debt refinancing, were important considerations as part of the decision to suspend the dividend,&#8221; the company said. 
&#8220;WBA leadership remains focused on successfully executing against its strategic priorities and maintaining financial discipline, which it believes will deliver sustained value creation over the long term.&#8221;
<h1 class="wp-block-heading">How To Buy WBA Stock</h1>
By now you're likely curious about how to participate in the market for Walgreens — be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share. 
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading — either way it allows you to profit off of the share price decline.
WBA Price Action: <a href="http://benzinga.com/quote/wba">Walgreens shares</a> were down 7.77% after-hours, trading at $10.52 at the time of publication Thursday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/43355688/apple-q1-earnings-revenue-beat-eps-beat-iphone-sales-slip-installed-base-climbs-to-all-time-high-our-best-quarter-ever">Apple Q1 Earnings: Revenue Beat, EPS Beat, iPhone Sales Slip, Installed Base Climbs To All-Time High — &#8216;Our Best Quarter Ever&#8217;</a></li>
</ul>
Photo: Courtesy of Walgreens Boots Alliance.

Dividends

After-Hours Center

Walgreens Boots Alliance Shares Slide As Board Suspends Dividend

Otis Worldwide Non-GAAP EPS of $0.93 misses by $0.03, revenue of $3.68B beats by $50M

Sees FY25 revenue $14.1B-$14.4B, consensus $14.55B. Sees FY25 organic sales up 2%-4%. Sees FY25 operating profit $2.4B-$2.5B. Sees FY25 adjusted fr...

Otis Worldwide sees FY25 adjusted EPS 4.00-$4.10, consensus $4.12

Reports Q4 revenue $3.68B, consensus $3.63B. "Otis finished 2024 with solid fourth quarter results including high single digit adjusted EPS growth,...

Otis Worldwide reports Q4 adjusted EPS 93c, consensus 96c

Earnings Snapshot: Otis Worldwide reports mixed Q4, FY sales guidance beats

Otis Worldwide Corporation 2024 Q4 - Results - Earnings Call Presentation

Otis Worldwide Corporation (OTIS) Q4 2024 Earnings Call Transcript

Otis Worldwide Corporation ( ($OTIS) ) has released its Q4 earnings. Here is a breakdown of the information Otis Worldwide Corporation presented to...

Otis Worldwide Shows Strong Performance and Positive Outlook

Analyst Christopher Snyder from Morgan Stanley maintained a Hold rating on Otis Worldwide (OTIS – Research Report) and keeping the price target at ...

Otis Worldwide: Hold Rating Amid Mixed Financial Performance and Market Challenges

Wells Fargo Remains a Hold on Otis Worldwide (OTIS)

Otis Worldwide declares $0.39 dividend

OTIS

Press Releases

Otis Declares Quarterly Dividend of $0.39 per Share

Otis CEO to Speak at Morgan Stanley Conference

Students to Develop Urban Mobility Solutions Using AI

Otis Third Quarter 2024 Earnings Advisory

OTIS REPORTS THIRD QUARTER 2024 RESULTS

Otis Fourth Quarter 2024 Earnings Advisory

Otis Authorizes $2 Billion for Share Repurchase

OTIS REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS

Crane

Donaldson

Dover

ESAB

Flowserve

Fortive

Graco

Chart Industries

IDEX

Ingersoll Rand

Illinois Tool Works

JBT Marel

Lincoln Electric Holdings, Inc. - Common Shares

Lincoln Electric Holdings

Middleby

Mueller Industries

Nordson

Parker Hannifin

Pentair

RBC Bearings

Snap-on

SPX Techs

Stanley Black & Decker, Inc. Common Stock

Stanley Black & Decker

Watts Water Technologies, Inc. Class A Common Stock

Comments

Otis Worldwide

Interés en corto

Otis Worldwide (NYSE:OTIS) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL